{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:43:24Z","timestamp":1792190604597,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Head and Neck Pathol"],"DOI":"10.1007\/s12105-024-01618-5","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T08:02:01Z","timestamp":1709884921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chronic Lymphocytic Thyroiditis with Oncocytic Metaplasia Influences PD-L1 Expression in Papillary Thyroid Carcinoma"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0820-6541","authenticated-orcid":false,"given":"Vitor Barreto","family":"Santana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vit\u00f3ria Machado","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina Yunes","family":"Abrah\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietru Lentz Martins","family":"Cant\u00fa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosicler Luzia","family":"Brackmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele Moroni","family":"Pandolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liane Scheffler","family":"Marisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Remonatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Adolfo","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia Silveira","family":"Graudenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"1618_CR1","doi-asserted-by":"publisher","unstructured":"Ahn D et al (Nov. 2011) Clinical relationship between Hashimoto\u2019s thyroiditis and papillary thyroid cancer. Acta Oncol 50(8):1228\u20131234. https:\/\/doi.org\/10.3109\/0284186X.2011.602109","DOI":"10.3109\/0284186X.2011.602109"},{"key":"1618_CR2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02158","author":"F Pacini","year":"2006","unstructured":"Pacini F et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/eje.1.02158","journal-title":"Eur J Endocrinol"},{"key":"1618_CR3","unstructured":"Thyroid Cancer \u2014 Cancer Stat Facts. Accessed: Sep. 06, 2022. [Online]. Available: https:\/\/seer.cancer.gov\/statfacts\/html\/thyro.html"},{"key":"1618_CR4","doi-asserted-by":"publisher","unstructured":"Chowdhury S et al (May 2016) Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget 7:32318\u201332328. https:\/\/doi.org\/10.18632\/oncotarget.8698","DOI":"10.18632\/oncotarget.8698"},{"key":"1618_CR5","doi-asserted-by":"publisher","unstructured":"Wan B et al (2021) Association between programmed cell death ligand 1 expression and thyroid cancer: a meta-analysis. Medicine 100(14). https:\/\/doi.org\/10.1097\/MD.0000000000025315","DOI":"10.1097\/MD.0000000000025315"},{"key":"1618_CR6","doi-asserted-by":"publisher","unstructured":"Girolami I et al (2020) Prevalence of PD-L1 expression in head and neck squamous precancerous lesions: a systematic review and meta-analysis, Head and Neck, vol. 42, no. 10. John Wiley and Sons Inc., pp. 3018\u20133030, Oct. 01, https:\/\/doi.org\/10.1002\/hed.26339","DOI":"10.1002\/hed.26339"},{"key":"1618_CR7","doi-asserted-by":"publisher","unstructured":"Mehnert JM et al (Mar. 2019) Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer 19(1):196. https:\/\/doi.org\/10.1186\/s12885-019-5380-3","DOI":"10.1186\/s12885-019-5380-3"},{"issue":"9","key":"1618_CR8","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1089\/thy.2014.0134","volume":"24","author":"TE Angell","year":"2014","unstructured":"Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL (2014) BRAFV600Ein papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid 24(9):1385\u20131393. https:\/\/doi.org\/10.1089\/thy.2014.0134","journal-title":"Thyroid"},{"issue":"2","key":"1618_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/ERC-16-0421","volume":"24","author":"S Ahn","year":"2017","unstructured":"Ahn S et al (2017) Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer 24(2):97\u2013106. https:\/\/doi.org\/10.1530\/ERC-16-0421","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"1618_CR10","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00428-018-2357-6","volume":"472","author":"Y Bai","year":"2018","unstructured":"Bai Y et al (2018) In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related. Virchows Arch 472(5):779\u2013787. https:\/\/doi.org\/10.1007\/s00428-018-2357-6","journal-title":"Virchows Arch"},{"issue":"1","key":"1618_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.yexmp.2016.01.004","volume":"100","author":"X Zhu","year":"2016","unstructured":"Zhu X et al (2016) Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma. Exp Mol Pathol 100(1):236\u2013241. https:\/\/doi.org\/10.1016\/j.yexmp.2016.01.004","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"1618_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1530\/ERC-12-0313","volume":"20","author":"LL Cunha","year":"2013","unstructured":"Cunha LL et al (2013) Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation. Endocr Relat Cancer 20(1):103\u2013110. https:\/\/doi.org\/10.1530\/ERC-12-0313","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"1618_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/thy.2016.0228","volume":"27","author":"RL Shi","year":"2017","unstructured":"Shi RL et al (2017) Programmed death-ligand 1 expression in papillary thyroid Cancer and its correlation with clinicopathologic factors and recurrence. Thyroid 27(4):537\u2013545. https:\/\/doi.org\/10.1089\/thy.2016.0228","journal-title":"Thyroid"},{"issue":"1","key":"1618_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.surg.2017.04.033","volume":"163","author":"MJ Aghajani","year":"2018","unstructured":"Aghajani MJ, Yang T, McCafferty CE, Graham S, Wu X, Niles N (2018) Predictive relevance of programmed cell death protein 1 and tumor-infiltrating lymphocyte expression in papillary thyroid cancer. Surg (United States) 163(1):130\u2013136. https:\/\/doi.org\/10.1016\/j.surg.2017.04.033","journal-title":"Surg (United States)"},{"issue":"3","key":"1618_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.pathol.2019.11.007","volume":"52","author":"M Fadia","year":"2020","unstructured":"Fadia M, Fookeerah P, Ali S, Shadbolt B, Greenaway T, Perampalam S (2020) PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study. Pathology 52(3):318\u2013322. https:\/\/doi.org\/10.1016\/j.pathol.2019.11.007","journal-title":"Pathology"},{"issue":"3","key":"1618_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4158\/EP-2018-0342","volume":"25","author":"GQ Zhang","year":"2019","unstructured":"Zhang GQ et al (2019) Programmed cell death-ligand 1 overexpression in thyroid cancer. Endocr Pract 25(3):279\u2013296. https:\/\/doi.org\/10.4158\/EP-2018-0342","journal-title":"Endocr Pract"},{"key":"1618_CR17","doi-asserted-by":"publisher","unstructured":"Zanoni DK, Patel SG, Shah JP Changes in the 8 th Edition of the American Joint Committee on Cancer (AJCC) staging of Head and Neck Cancer: Rationale and implications, https:\/\/doi.org\/10.1007\/s11912-019-0799-x","DOI":"10.1007\/s11912-019-0799-x"},{"key":"1618_CR18","doi-asserted-by":"publisher","unstructured":"Amin MB et al (2017) Mar., The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u2018personalized\u2019 approach to cancer staging, CA Cancer J Clin, vol. 67, no. 2, pp. 93\u201399, https:\/\/doi.org\/10.3322\/CAAC.21388","DOI":"10.3322\/CAAC.21388"},{"key":"1618_CR19","doi-asserted-by":"publisher","unstructured":"Bill R, Faquin WC, Pai SI (2023) Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations, Head and Neck Pathology. Springer, Dec. 01, https:\/\/doi.org\/10.1007\/s12105-023-01590-6","DOI":"10.1007\/s12105-023-01590-6"},{"issue":"2","key":"1618_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pathol.2020.10.007","volume":"53","author":"EC Paver","year":"2021","unstructured":"Paver EC et al (2021) Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology 53(2):141\u2013156. https:\/\/doi.org\/10.1016\/j.pathol.2020.10.007","journal-title":"Pathology"},{"issue":"4","key":"1618_CR21","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in Cancer Immunotherapy. Mol Cancer Ther 14(4):847\u2013856. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0983","journal-title":"Mol Cancer Ther"},{"key":"1618_CR22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","author":"EB Garon","year":"2015","unstructured":"Garon EB et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"key":"1618_CR23","doi-asserted-by":"publisher","unstructured":"Rimm DL et al (2017) Aug., A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non\u2013small cell lung cancer, JAMA Oncol, vol. 3, no. 8, pp. 1051\u20131058, https:\/\/doi.org\/10.1001\/JAMAONCOL.2017.0013","DOI":"10.1001\/JAMAONCOL.2017.0013"},{"key":"1618_CR24","doi-asserted-by":"publisher","unstructured":"Adam J et al (2018) Apr., Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer, Ann Oncol, vol. 29, no. 4, pp. 953\u2013958, https:\/\/doi.org\/10.1093\/ANNONC\/MDY014","DOI":"10.1093\/ANNONC\/MDY014"},{"issue":"1","key":"1618_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4132\/jptm.2017.07.26","volume":"52","author":"HJ An","year":"2018","unstructured":"An HJ et al (2018) Programmed death-ligand 1 expression and its correlation with lymph node metastasis in papillary thyroid carcinoma. J Pathol Transl Med 52(1):9\u201313. https:\/\/doi.org\/10.4132\/jptm.2017.07.26","journal-title":"J Pathol Transl Med"},{"key":"1618_CR26","unstructured":"Franks AL, Slansky JE Multiple Associations Between a Broad Spectrum of Autoimmune Diseases, Chronic Inflammatory Diseases and Cancer, Anticancer Res, vol. 32, no. 4, p. 1119, Apr. 2012, Accessed: Oct. 01, 2022. [Online]. Available: \/pmc\/articles\/PMC3349285\/"},{"key":"1618_CR27","doi-asserted-by":"publisher","unstructured":"Ehlers M, Schott M (Dec. 2014) Hashimoto\u2019s thyroiditis and papillary thyroid cancer: are they immunologically linked? Trends Endocrinol Metab 25(12):656\u2013664. https:\/\/doi.org\/10.1016\/J.TEM.2014.09.001","DOI":"10.1016\/J.TEM.2014.09.001"},{"key":"1618_CR28","doi-asserted-by":"publisher","unstructured":"Lubin D, Baraban E, Lisby A, Jalali-Farahani S, Zhang P, Livolsi V (2018) Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis, Endocr Pathol, vol. 29, no. 4, pp. 317\u2013323, Dec. https:\/\/doi.org\/10.1007\/S12022-018-9540-9","DOI":"10.1007\/S12022-018-9540-9"},{"key":"1618_CR29","doi-asserted-by":"publisher","unstructured":"Dell\u2019Aquila M et al (2022) Oct., Update regarding the role of PD-L1 in oncocytic thyroid lesions on cytological samples, J Clin Pathol, https:\/\/doi.org\/10.1136\/jclinpath-2022-208215","DOI":"10.1136\/jclinpath-2022-208215"},{"key":"1618_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30360","author":"BR Haugen","year":"2017","unstructured":"Haugen BR (2017) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: what is new and what has changed? Cancer. https:\/\/doi.org\/10.1002\/cncr.30360","journal-title":"Cancer"},{"key":"1618_CR31","doi-asserted-by":"publisher","unstructured":"Tuttle RM, Haugen B, Perrier ND (2017) Updated American Joint Committee on Cancer\/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? Thyroid, vol. 27, no. 6, pp. 751\u2013756, Jun. https:\/\/doi.org\/10.1089\/THY.2017.0102","DOI":"10.1089\/THY.2017.0102"}],"container-title":["Head and Neck Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-024-01618-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12105-024-01618-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-024-01618-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:20:16Z","timestamp":1736349616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12105-024-01618-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1618"],"URL":"https:\/\/doi.org\/10.1007\/s12105-024-01618-5","relation":{},"ISSN":["1936-0568"],"issn-type":[{"value":"1936-0568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]},"assertion":[{"value":"12 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. This study was approved by the Ethics Committee of Hospital de Clinicas de Porto Alegre\/CEP-HCPA - (CAAE-44034920.2.0000.5327).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This study obtained IRB approval from (CEP-HCPA) and the need for informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Consent for publication was not required for this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}],"article-number":"14"}}